CABS BioPacific Conference 2015

17TH ANNUAL CONFERENCE OF THE CHINESE AMERICAN BIOPHARMACEUTICAL SOCIETY

CABS
Chinese American Biopharmaceutical Society
北美华人生物医药协会




Opportunities, Challenges, & Growth – A New Era in Biomedical Innovation & Discovery

Date and Time: May 9th, Saturday, 2015, 9:00AM-9:00PM

Location: San Mateo Marriott, 1770 South Amphlett Blvd., San Mateo, CA 94402

OUR MISSION

- *To serve biopharmaceutical professionals with professional interests in China and promote professional interactions locally and across the Pacific*
- *To foster business opportunities and exchanges in the life science industry between the U.S. and China*
- *To promote public awareness of progress and development in the pharmaceutical and biotechnological industry*
- *To collaborate with other organizations in areas of mutual interest*

CABS
Chinese American Biopharmaceutical Society
北美华人生物医药协会

CABS Contact Information
（美华药协联系信息）

Mailing Address（ 邮政地址）
268 Bush Street, #1888
San Francisco, CA 94104, USA

Website（网页地址）
www.cabsweb.org
www.biopacificconference.org

Email（电子邮件信箱）
General information
（一般信息）：
Info@CABSweb.org

Membership（会员申请）：
Membership@CABSweb.org

Fundraising（募捐）：
Fundraising@CABSweb.org

Brochure Design
（会议手册设计）
Xiaojun Li

Brochure Production
（会议手册制作）
CABS Publication Committee 2015

BIOPACIFIC CONFERENCE 2015
Chinese American Biopharmaceutical Society (CABS)

TABLE OF CONTENTS

**The official working language of the conference is English*

Remarks from the President
of the Chinese American Biopharmaceutical Society (CABS)



Welcome to the 2015 BioPacific Conference, the 17th annual conference of the Chinese American Biopharmaceutical Society (CABS).

First of all, I would like to thank President-elect, Jiangwen Majeti, the entire organizing committee, and volunteers who have worked tirelessly for the past few months in planning this Conference.

2014 has been a fantastic year for the biopharmaceutical industry with record FDA approvals, a booming biotech IPO market, increased funding opportunities, and active mergers and acquisitions. Therapeutics targeting the cures of some serious diseases are close to reality. While innovation is dramatically improving human life, the costs of innovative medicines are increasingly becoming a concern, so the future growth of biopharmaceutical industry will face the challenge of sustainability. Today's conference will focus on the opportunities and challenges of biomedical innovation and discovery. I am glad to bring together our members, sponsors, and scientific and business leaders from both sides of the Pacific Rim in today's conference.

As a non-profit organization run by volunteers, CABS has become a major scientific and business forum for professionals from the biopharmaceutical industry and life science community in the San Francisco Bay Area. We try hard to serve our members by providing a series of programs. Among them, scientific seminars and educational workshops, on a regular basis, provide members the opportunity to gain knowledge from different disciplines and to stay informed with the newest technologies; E-club provides a platform for future biotech entrepreneurs to get together and share ideas; for career development, and the Career Action Network (CAN) mentoring program pairs junior professionals with more seasoned professionals for an invaluable experience. As China emerges to become one of the biggest players in the biopharmaceutical industry, CABS has served an increasingly important role in facilitating the collaboration between the biopharmaceutical communities in the US and China. Our annual delegation to China gives members an incredible opportunity to connect with the pharmaceutical industry and science parks in China.

We are proud to have Dr. Irving Weissman as the winner of the 2015 CABS K. Fong Award in Life Sciences. The award recognizes Professor Weissman's significant contributions to life sciences, in particular, groundbreaking discovery of hematopoietic stem cells and human central nervous system stem cell, and his contributions to understanding pathways of stem cell to cancer transitions. His pioneering scientific discoveries continue to translate science into better medicine for the patients.

Thank you for your support of CABS and I hope that you enjoy the conference.

With warm regards,

Xiaolin Alan Hao, Ph.D.

President, CABS

ABOUT **CABS**

WHO WE ARE

The Chinese American Biopharmaceutical Society (CABS), headquartered in San Francisco, California, is a non-profit organization for professionals in the biopharmaceutical industry. We are fully run by enthusiastic and dedicated volunteers and have over 3,000 members and participants. Our members are located in the San Francisco Bay Area, the largest biotechnology hub of the world and the birthplace of biotechnology, as well as in other parts of the US and Pacific Rim countries including China. While the majority of our members are scientists in biopharmaceutical companies, universities and research institutions, we also have a strong presence of professionals from life sciences-focused legal, financial, and venture capital firms. Three quarters of our members have a doctorate degree and approximately half of our members hold leadership and management positions in the biopharmaceutical industry.

WHAT WE DO

To fulfill our mission, we organize frequent activities, such as scientific and business workshops and social/networking events. Our flagship event is our annual conference, the BioPacific Conference, which attracts about 600 attendees from the US and the Pacific Rim. Each year, CABS sends a delegation to China to promote professional interaction and generate business opportunities. We also host frequent business exchange meetings with delegations from China seeking talent and technologies from the U.S.

北美华人生物医药协会(美华药协)简介

北美华人生物医药协会(美华药协)是一个非盈利性的生物医药专业协会。 该协会总部位于旧金山湾区，这里不仅是硅谷所在地, 也是生物科技的起源地及全球最大的生物科技重镇, 有逾千家大小型的生物制药公司， 包括几家全球最有影响力的公司Amgen，Genentech和Gilead。我们协会是一个有三千多名成员组成的有重大影响力的生物医药专业协会。成员中70% 拥有生物医药及相关领域的博士学位，有相当比例的成员担任美国生物医药公司高级研究及管理职位，不少是生物医药科技各领域的专家及学术带头人，也有勇于创业创新的企业家， 知识产权律师和风险投资人士。作为北美最大最为活跃的华人生物医药协会，及置身于生物医药第一重镇的独特条件，美华药协广泛开展促进中美生物医药交流，为中国的科技园区及生物医药行业提供一个理想的推介与吸引科技项目与人才的平台。 除我们经常举办的科技与商业研讨会之外，我们每年举办的 BioPacific Conference 太平洋生物大会已被 视为生物医药界一个促进中美交流的主要活动之一，吸引来自美国和中国的数百名从事生物制药业的专业人士和企业领袖参加。我们创办的专业杂志 “ 国际医药动态 ” 也是我们促进中美交流的重要渠道。

BioPacific Conference 2015
Organizing Committee

Jiangwen Majeti, Ph.D., M.B.A. *BioDuro*

Xiaolin Alan Hao, Ph.D. *AIM Biosciences*

Howard Huang, M.S. *CPC Scientific*

Alex Zhang, Ph.D., M.B.A *AutekBio*

Chi-Hui Tang, Ph.D. *Medidata Solutions*

Yang Tian, Ph.D. *Gilead Sciences*

Liping Meng, Ph.D. *Gilead Sciences*

Carrie Kaiyue Wang, M.D. *Concept to Clinic*

Lei Lei, M.S. *Boster Biological*

Jiwen (Jim) Liu, Ph.D. *Amgen*

Shichang Miao, Ph.D. *ChemoCentryx*

Janet Xiao, Ph.D., J.D. *Morrison & Foerster LLP*

Zhenhai Shen, Ph.D., M.B.A. *Genentech*

CABS Leadership

Board of Directors
Wei Dong, M.D., Ph.D.
Alan Hao, Ph.D.
Jing-Shan Hu, Ph.D.
Leping Li, Ph.D.
Shichang Miao, Ph.D.
Zhonghua Pei, Ph.D.
Jun Xiang, Ph.D.
Janet Xiao, Ph.D., J.D.
Naibo Yang, Ph.D.
Wentao Zhang, Ph.D.

Advisory Board
Baolu Chen, Ph.D.
Keting Chu, M.D., Ph.D.
John Wang, Ph.D.
Guoliang Yu, Ph.D.
Cheng Li, Ph.D.
DQ Wang, Ph.D.
Yingfei Wei, Ph.D.

2015 Executive Council

President
Xiaolin Alan Hao, Ph.D. AIM Biosciences

President-Elect
Jiangwen Majeti, Ph.D., M.B.A. BioDuro

Past President
Zhonghua Pei, Ph.D. Genentech

Webmaster
Zhengping Huang, Ph.D. Novartis

Treasurer
David Wang, B.S., C.P.A.

Bookkeeper
Yao Long, B.S. Epitomics, Inc.

Business & Career Development

Co-chairs
Cheni Kwok, Ph.D., CLP Linear Dreams
Sean Xiang Wu, Ph.D. Quintara Discovery

Elected Members
Li Tai Fang, Ph.D. Bina Technologies
Shenshen Hu, Ph.D. UC Berkeley
Ting Jia, Ph.D. BVF Partners L.P.

Appointed Members/Volunteers
Jian Cao, Ph.D. Centrillion Biosciences, Inc.
Lynn Guo, Ph.D. candidate Genentech
Fanglin Lu, M.S. Thermo Fisher
Xiangling Xiong, Ph.D. Impax
Han Zhang, Ph.D. Stanford University

Fundraising

Co-chairs
Howard Huang, M.S. CPC Scientific
Alex Zhang, Ph.D., M.B.A AutekBio

Elected Members
Taotao Chen, Ph.D. LakePharma
Wei Huang, Ph.D. Newa Technology, Inc.
Wen Kumfert, Ph.D. Bio-Rad Laboratories

Appointed Members/Volunteers
Lijuan Ji, Ph.D. Stanford University
Gavin Lu, Ph.D., Eureka Therapeutics

International Collaboration

Co-chairs
Zhenhai Shen, Ph.D., M.B.A Genentech
Yan Wang, Ph.D. Gazelle Technologies

Elected Members
Wenjing Chen, Ph.D. LakePharma
Norman Zhou, Ph.D. Genentech

Appointed Members/Volunteers
Hao Wu, Ph.D. UCSF

Membership

Co-chairs
Liping Meng, Ph.D. Gilead Sciences
Yang Tian, Ph.D. Gilead Sciences

Elected Members
Yonghua Pan, Ph.D. Dynavax Technologies
Lin Yan, Ph.D. StemCells, Inc

Appointed Members/Volunteers
Zhican Wang, Ph.D. Amgen
Jingqing Zhang, Ph.D. 6SensorLabs, Inc

Operations

Chair
Carrie Kaiyue Wang, M.D. Concept to Clinic

Elected Members
Lei Lei, M.S. Boster Biological
Sihong Zhou Sutro Biopharma

Publication & Communication

Co-chairs
Lei Lei, M.S. Boster Biological
Chi-Hui Tang, Ph.D. Medidata Solutions

Elected Members
Veronica Huang, Ph.D. UC Berkeley
Yongke Zhang, Ph.D. Apexigen

Appointed Members/Volunteers
Jiwen (Jim) Liu, Ph.D. Amgen

Science & Technology

Co-chairs
Jianlong Lou, M.D., Ph.D. UCSF
Jessica Sun, Ph.D. Threshold Pharmaceuticals

Elected Members
Jiwen (Jim) Liu, Ph.D. Amgen
Ann Mongan, Ph.D. Thermo Fisher Scientific
Wei Zhang, Ph.D. Apton Biosystems

Social Life

Co-chairs
Bo Lian, Ph.D. Onyx Pharmaceuticals
Jian Zhang, Ph.D. Amgen

Elected Members
Lingjie Guan, Ph.D. Bayer
Youling Zou, M.S. Baidu

Appointed Members/Volunteers
Fanglin Lu, M.S. Thermo Fisher Scientific
Shuyi Zhuang, M.S. Gilead Sciences

CABS Membership Demographics

Overall Membership

Our membership consists of life science professionals from a broad range of experience levels. A large percentage of our members hold senior or executive positions in the industry, and we are proud to have numerous entrepreneurs who have successfully started and sold life science companies in our pedigree. In addition, we continue to attract new talent from the local academic institutions (UC Berkeley, UC San Francisco, and Stanford University, among others).



LinkedIn Membership

Our LinkedIn Group has also seen continued growth over the last year and is becoming an increasingly important component in our mission of promoting public awareness of the life science industry, encouraging business opportunity and exchange, and serving as a bridge for the life science industry throughout the Asia Pacific.

URL: https://www.linkedin.com/grp/home?gid=695127

Membership as of April 20, 2015: 545



BIOPACIFIC CONFERENCE 2015

SPONSORS LIST

Platiumn

Gold

Silver

ALLIANCE PARTNERS

BIOPACIFIC CONFERENCE 2015

AGENDA

Time: May 9, 2015, Saturday

Location: San Mateo Marriott
1770 South Amphlett Blvd.
San Mateo, CA 94402

8:00 – 9:00 **Registration & Vendor Exhibition**

9:00 – 9:05 **Opening Remarks**

Jiangwen Majeti, Ph.D., MBA, CABS President-elect & 2015 BioPacific Conference Organizing Committee Chair

9:05 – 9:15 **State of the Society**
Alan Hao, Ph.D., CABS President

9:15 – 10:05 **CABS K. Fong Award in Life Sciences & Keynote Speech**
Award Winner: Dr. Irving Weissman
Irving Weissman, M.D., Virginia & D. K. Ludwig Professor, Stanford University
Normal and Neoplastic Stem Cells

10:05 – 12:20 **Developing Novel Therapies through Discovery and Technology Innovation**
Session Chair: Shichang Miao, Ph.D.

10:05 – 10:40 Allen Ebens, Ph.D., Senior Director of Research, Juno Therapeutics
Adoptive Cell Therapies for Cancer: Challenges and Opportunities

10:40 – 11:10 **Coffee Break** Vendor Exhibition & Networking

11:10 – 11:45 Jerry Shen, Ph.D., Executive Director of Biology, BioMarin Pharmaceutical, Inc.
BioMarin, a SF/Bay Area Growth Story

11:45 – 12:20 Peter Staehr, M.D., Ph.D., Senior Director, Global Trials, Abbott Vascular
Development of a Coronary Bioresorbable Scaffold - The Next Revolution in Interventional Cardiology

12:20 – 12:40 Thomas Irving, J.D., Partner, Finnegan
Developing U.S. Patents for Novel Therapies Through Discovery and Technology Innovations

12:40 – 1:30 **Lunch**

1:30 – 2:50 **Celebrating Bay Area Biotech Industry Organic Growth**
Session Chair: Jiwen Liu, Ph.D.

1:30 – 2:00 Jin-Long Chen, Ph.D., Founder & Chief Scientific Officer, NGM Biopharmaceuticals, Inc.
Building an "Old School" Biotech Company to Discover Novel Biological Medicines

2:00 – 2:30 Aaron Sato, Ph.D., Vice President of R&D, Sutro Biopharma
Sutro Biopharma: A Bay Area Biotech Veteran that Reinvented Itself

2:30 – 2:50 Stephen Thau, JD, Partner, Morrison & Foerster LLP
Status Update for Deals and Financings in Biotechnology

2:50 – 3:15 **Platinum and Gold Sponsor Presentations**
Lorraine Lu, M.Phil., Marketing Manager, Cyagen Biosciences
Eric Zhang, Ph.D., Founder & CEO, Shandong Kaisen Pharma
Jasmine Cui, Ph.D., GM & CSO, BioDuro, a PPD company

3:15 – 3:45 **Coffee Break** Vendor Exhibition & Networking

3:45 – 5:00 **US/China Biomedical Science Funding Trend**
Session Chair: Howard Huang, M.S.

3:45 – 4:10 Ming Zhao, Ph.D., Program Director, SBIR Development Center, NCI
NCI SBIR & STTR: Advancing the Commercialization of New Cancer Innovation

4:10 – 4:35 Darren Ji, Ph.D., MBA, Global Head & Vice President, Asia and Emerging Markets Partnering, F. Hoffmann-La Roche
Maximizing the Capital Efficiency for Drug R&D through Creative Partnerships

4:35 – 5:00 Jimmy Z. Zhang, Ph.D., MBA, Vice President, Transactions, J&J Innovation, Asia Pacific.
New Ways to Source and Fund Innovations

5:00 – 5:20 **Gold Sponsor Presentations**
Zeke Li, M.D., Senior Vice President of Corporate Development, Frontage Laboratories
Connie Sun, Ph.D., Senior Vice President of Business and Corporate Development, Pharmaron
Cheni Kwok, Ph.D., CLP, Senior Consultant, Business Development, Shanghai Medicilon

5:20 – 6:00 **Happy Hour**

6:00 – 7:00 **Dinner**

7:00 – 8:30 **New Therapeutic Development in China**
Session Chairs: Tao Huang, Ph.D., J.D. and Cheni Kwok, Ph.D., CLP

7:00 – 7:20 Chengbin Wu, Ph.D., Chief Scientific Officer and President, Shanghai CP Guojian Pharmaceuticals Co., Ltd.
Developing Therapeutic Antibodies in China: Biosimilars and Beyond

7:20 – 7:40 Dechao Yu, Ph.D., President & CEO, Innovent Biologics, Inc.
Innovative Biologics in China: Challenges and Opportunities

7:40 – 8:00 Weidong Jiang, Ph.D., Chief Scientific Officer & Vice President, Henlius Biopharmaceuticals Inc.
Antibody Therapeutics in China: A Challenging Pathway

8:00 – 8:20 Lan Huang, Ph.D., Co-Founder & CEO, BeyondSpring Pharmaceuticals, Inc.
New US-China Integration Model for Innovative Drug Development for the Global Market

8:20 – 8:30 Group Q & A

8:30 **Conference Adjourned**

** The official working language of the conference is English*

Keynote Speaker
Irving L. Weissman, M.D.
Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine
Director, Stanford Ludwig Center for Cancer Stem Cell Research and Medicine
Professor of Pathology and Developmental Biology
Stanford University

Normal and Neoplastic Stem Cells

Following embryonic development, most of our tissues and organs are continuously regenerated from tissue/organ specific stem cells. The principal property that distinguishes such stem cells from their daughter cells is self-renewal; when stem cells divide they give rise to stem cells (by self-renewal) and progenitors (by differentiation). In most tissues only the primitive stem cells self-renew. Stem cell isolation and transplantation is the basis for regenerative medicine. In the 1990s, we isolated mouse and human hematopoietic (blood-forming) stem cells (HSCs), and found that their method of isolation depleted all detectable cancer cells from mobilized peripheral blood (MPB) from patients with breast cancer. We used patients' MPB or cancer-free HSCs in autologous transplantations to rescue the hematopoietic system of women who underwent high dose combination chemotherapy for stage IV breast cancer. The results with MPB autologous transplantation were similar to those reported previously, with a 12–15-year overall survival rate of ~7%. In contrast, for contemporaneous patients in a small phase I/II trial at Stanford who received autologous transplants with cancer-free HSCs, this survival rate was ~33%. By chi-square analysis, MPB vs. cancer-free HSC transplantations were significantly different in terms of both progression-free and overall survival at all time points tested from 20 months to 12-15 years after transplantation.

In considering stem cells and cancer, self-renewal is dangerous and therefore strictly regulated. Poorly regulated self-renewal can lead to the genesis of cancer stem cells, the only self-renewing cells in the cancerous tumor. We have followed the progression from HSCs to myelogenous leukemias and found that the developing cancer clones progress at the stage of HSCs, until they become fully malignant. At this point, the "leukemia" stem cell moves to a stage of a downstream oligolineage or multilineage progenitor that has evaded programmed cell death and programmed cell removal, while acquiring or keeping self-renewal. In the case of chronic myeloid leukemia, bcr-abl+ HSC clones outcompete normal HSCs in the chronic phase. The transition from the chronic phase to myeloid blast crisis results in the leukemia stem cells appearing in the granulocyte-macrophage progenitor (GMP) stage, and is accompanied by cell intrinsic activation of β-catenin, inhibitable by transfection with axin. In 4 of 7 patients studied, this resulted from stage-specific (GMP) mis-splicing of the glycogen synthase kinase–3β message, deleting the kinase domain. With the Majeti and Quake labs, we have shown that the mutations/indels (insertions or deletions) in 5 FLT3-ITD (internal tandem duplication) acute myeloid leukemias (AMLs) occur successively in HSC clones, including the penultimate FLT3-ITD itself. Of interest, many of the founder mutations are in epigenetic modifier genes such as TET2.

While there are many ways to defeat programmed cell death and senescence, there appears to be one dominant method to avoid programmed cell removal—the expression of the cell surface "don't eat me" protein CD47, the ligand for macrophage SIRPα. All cancers we tested express CD47 to overcome expression of "eat me" signals such as calreticulin. In leukemias and lymphomas, calreticulin is the "eat me" signal countermanded by the CD47 "don't eat me" signal. In myelodysplastic syndrome (MDS), we found that MDS-initiating HSC clones outcompete normal HSC clones in the patient and in mice that receive xenotransplants of patient HSC samples. However, the oligolineage progenitors downstream of HSCs (e.g., GMPs) express calreticulin but not CD47, leading to our hypothesis that the blood-cell deficiencies in MDS occur because the progenitors are phagocytosed in vivo. When CD47 is upregulated in the MDS clone, MDS progresses to refractive anemia with excess blasts or AML. Other labs have also found mutations in the calreticulin gene in myeloproliferative neoplasms and MDS.

Antibodies that block the CD47–SIRPα interaction enable phagocytosis and killing of the tumor cells in vitro and in vivo. All tested human solid tumors and lymphomas/leukemias/myelomas express CD47 and are susceptible to phagocytosis in the presence of anti-CD47 blocking antibodies, including a humanized antibody of the IgG4 isotype. Anti-CD47 antibodies synergize with IgG1 cancer antibodies—such as rituximab, trastuzimab, and cetuximab—to shrink or eliminate primary human cancers xenografted into NSG mice. In this synergistic therapy, the IgGl antibodies supply a strong 'eat me' signal. In these studies, a high-affinity variant of the human SIRPα binding domain, administered alone as a monomer or fused to IgG4, can replace the anti-CD47 antibodies. In addition, anti-CD47–facilitated phagocytosis of DLD-1-OVA greatly augments the cross-presentation of OVA peptides to mouse OT-1 CD8 T cells in vitro and in vivo. We expect to have the anti-CD47 therapies in phase I trials in 2014. In these trials, we will test whether patients' anti-tumor T cells are stimulated.

About the speaker

Irving L. Weissman, M.D., is the Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and Director of the Stanford Ludwig Center for Cancer Stem Cell Research. Dr. Weissman was a member of the founding Scientific Advisory Boards of Amgen (1981-1989), DNAX (1981-1992), and T-Cell Sciences (1988-1992). He co-founded, was a Director, and chaired the Scientific Advisory Board at SyStemix (1988-1996), StemCells Inc. (1996-present), and Cellerant (2001-2009).

His research encompasses the biology and evolution of stem cells and progenitor cells, mainly blood-forming and brain-forming. He is also engaged in isolating and characterizing the rare cancer and leukemia stem cells as the only dangerous cells in these malignancies, especially with human cancers. He discovered that all cancer stem cells express CD47, the 'don't eat me' signal, to overcome prophagocytic signals that arise during cancer development, and has shown that blocking antibodies to CD47 have therapeutic potential for all tested human cancers. Finally, he has a long-term research interest in the phylogeny and developmental biology of the cells that make up the blood-forming and immune systems. His laboratory was first to identify and isolate the blood-forming stem cell from mice, and has purified each progenitor in the stages of development between the stem cells and mature progeny (granulocytes, macrophages, etc). At SyStemix, he co-discovered the human hematopoetic stem cell, and at StemCells Inc., he co-discovered a human central nervous system stem cell. In addition, the Weissman laboratory at Stanford has pioneered the study of the genes and proteins involved in cell adhesion events required for lymphocyte homing to lymphoid organs in vivo, either as a normal function or as events involved in malignant leukemic metastases.

Professor Weissman is a member of the Council and Institute of Medicine at the National Academy of Sciences, and a member of the American Association of Arts and Sciences. He has received many awards, including the New York Academy of Medicine Award for Distinguished Contributions to Biomedical Research, the Pasarow Award in Cancer Research, the California Scientist of the Year, the De Villiers International Achievement Award of the Leukemia Society of America, the Robert Koch Award, the Rosenstiel Award, the Max Delbruck Medal, the Jessie Stevenson Kovalenko Award of the National Academy of Sciences, and most recently the Charles Rodolphe Brupbacher Prize for Cancer Research. He also has several honorary doctorates.

Allen Ebens, Ph.D.
Senior Director of Research
Juno Therapeutics

Adoptive Cell Therapies for Cancer: Challenges and Opportunities

Pioneering efforts in immune checkpoint blockade have provided abundant clinical evidence of host immune responses against cancer and the durability of responses in some cases suggests that a new generation of curative therapies is now within reach. However, it remains unclear what proportion of patients have a sufficient host immune response to obtain benefit from checkpoint therapies and there also remains significant room for improvement in autoimmune side effect profiles.

For patients where a significant anti-tumor immune response does not exist, complimentary approaches will be required to redirect immune cells to recognize tumor. Recent clinical successes have fueled a resurgence of interest in adoptive cell-based therapies (ACT), and in particular, the use of recombinant chimeric antigen receptor (CAR) cells and T cell receptor (TCR) cells for cancer therapy. In particular, multiple investigators have reported phase I trial results in acute lymphoblastic leukemia (ALL) in the range of 80-90% complete response (CR) rates with promising durability in a subset of cases.

While current studies have provided clinical proof of concept for adoptive cell therapies, we have only just begun to explore the clinical potential of this approach. There exists a multitude of experimental manipulations that may enhance immune cell function and overcome immunosuppression in the tumor microenvironment. In addition, it is recognized that significant challenges remain with respect to manufacturing. These challenges, the current state of the art, and next generation technologies will be exemplified and discussed.

About the speaker

Allen Ebens currently leads Discovery Research at Juno Therapeutics in Seattle where he is responsible for discovery and advancement of new technologies and cell-based therapies for the chimeric antigen receptor (CAR) and T-cell receptor (TCR) platforms. Prior to Juno, Allen was in Genentech Research for 11 years where he had a number of different roles, including leadership of the antibody-drug conjugate team, the bispecific T-cell recruiting antibody team, and the cancer immunotherapy department. These efforts resulted in more than half a dozen clinical candidates currently in various stages of development.

Prior to Genentech, Allen was at Exelixis Pharmaceuticals for 6 years in several different roles. Allen received his B.Sc. in Chemistry from the University of Washington in Seattle, and his Ph.D. in Molecular Biology at UCLA. He went on to complete postdoctoral training with Marc Tessier-Lavigne at UCSF prior to joining Exelixis.

SPEAKERS

Jerry Shen, Ph.D.
Executive Director of Biology
BioMarin Pharmaceuticals, Inc.

BioMarin, a San Francisco Bay Area Growth Story

BioMarin Pharmaceutical Inc. is a biopharmaceutical company based in San Rafael, California. Founded in 1997, BioMarin develops and commercializes innovative biopharmaceuticals for serious, life-threatening rare diseases and medical conditions. Starting with its core business in enzyme replacement therapies (ERTs), BioMarin now has four therapeutic platforms: protein therapy, small molecule drug therapy, gene therapy, and RNA therapy. Today, BioMarin has five products on the market, a robust clinical development portfolio, more than 1,500 employees, offices/facilities around the world, and a market cap of >$10 billion.

Among BioMarin's clinical development portfolio is talazoparib (BMN 673), a second-generation PARP inhibitor designed for the treatment of genetically-defined cancers (e.g. breast cancer and ovarian cancer with BRCA gene mutations). With its dual mechanism of action, talazoparib is the most potent PARP inhibitor reported so far and has a PK profile that supports once daily oral dosing. Talazoparib is highly active in mouse models of human cancer both as a single-agent treatment and in combination with other anti-cancer agents. Clinically, talazoparib was generally well tolerated and has shown promising single-agent anti-tumor efficacy in a Phase 1/2 clinical study in breast cancer and ovarian cancer with germline BRCA gene mutations, as well as in other solid tumors (reference below). Two separate clinical trials (one phase 2 and one phase 3) are currently on-going to further explore the efficacy of talazoparib in patients with metastatic breast cancers that harbor germline BRCA gene mutations.

Ref : Wainberg ZA et al. J Clin Oncol. 2014;32(suppl):5; abstr 7522

About the speaker

Dr. Yuqiao (Jerry) Shen is Executive Director of Biology at BioMarin. He previously served as Vice President of Biology at LEAD Therapeutics, Vice President of Research and Development at Applied Biomics, and Associate Director at ONYX Pharmaceuticals.

Dr. Shen trained as a post-doctoral fellow at Princeton University. He received his doctorate in Molecular Biology from the State University of New York at Buffalo, and Bachelor of Science in Biology from Fudan University in Shanghai.

Development of a Coronary Bioresorbable Scaffold – The Next Revolution in Interventional Cardiology

Peter Staehr, M.D., Ph.D.
Senior Director, Global Trials
Abbott Vascular

Percutaneous coronary intervention (PCI) is a classic example of revolutionary device development in medicine. However, at the same time, it demonstrates the challenges that the medical community and industry can encounter in their efforts to innovate a medical area.

During its early steps, balloon angioplasty (BA) was the only PCI treatment option, restricted to simple coronary anatomies; associated with a high risk of restenosis, other significant complications and limitations. The introduction of bare metal stents (BMS) was an important step forward as it reduced the risk of restenosis. However, the risk of stent thrombosis and "in-stent" restenosis emerged with BMS. The first drawback was addressed with the use of antithrombotic (antiplatelet) treatment while the second was managed with the introduction of drug eluting (metal) stents (DES) that actually eliminated the risk of restenosis. Nevertheless, DES had also drawbacks as they delayed vessel wall healing and endothelization, increased the occurrence of late wall malapposition with higher risk of late stent thrombosis, and, similar to BMS, continued vascular inflammation due to the permanent, foreign metal material which has been suspected to cause late neo-atherosclerosis. BMS and DES also impede the restoration of the vasomotor function of the stented segment. Bioresorbable scaffolds (BRS) have been introduced to overcome these limitations, since they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage.

This talk will outline the journey of PCI treatment with all its challenges over the past decades and, with the development of BRS, provide an example of a truly innovative and successful approach.

About the speaker

Peter Staehr, M.D., Ph.D., is Senior Director leading the worldwide Clinical Science group at Abbott Vascular. He oversees the clinical-scientific development of the entire drug-device and device products.

Prior to Abbott Vascular, Dr. Staehr gained extensive experience with increasing responsibilities in Clinical Drug Development from early "First-in Human" to "late" stage (phase 1-4) at various Pharmaceutical companies, including ALZA/Johnson & Johnson, CV Therapeutics/ Gilead, and Theravance. Among others, he was supporting the clinical efforts to obtain US-FDA and EMA drug approval of regadenoson (Lexiscan®, Rapiscan), indicated for the detection of myocardial ischemia with radionuclide perfusion imaging. Dr. Staehr is special task director and committee member of the Pharmaceutical & BioScience Society in the San Francisco Bay Area.

Dr. Staehr was trained and board-certified as internist and cardiologist at Johannes-Gutenberg University in Mainz/Germany and completed his postdoctoral training at Stanford University at the Center for Research in Cardiovascular Interventions.

Thomas L. Irving, J.D.
Partner
Finnegan

Developing U.S. Patents for Novel Therapies Through Discovery and Technology Innovations

Finnegan patent attorneys Thomas L. Irving, Dr. Wen Li, and Michael Liu Su will discuss strategies for developing and defending patents for novel therapies. They will cover critical issues a successful biopharmaceutical company must consider in growing its patent portfolio alongside product development. Even more importantly, they will discuss the highly popular Patent Office post-grant proceedings, through which third parties can challenge a biopharmaceutical company's patents. The Finnegan attorneys will then cover defense strategies.

About the speaker

Tom Irving is a partner with Finnegan, Henderson, Farabow, Garrett & Dunner, LLP in the Washington, DC, office. Having some 39 years of experience in the field of intellectual property law, Irving's very active practice includes due diligence, patent prosecution, reissue and reexamination, AIA post-grant proceedings, patent interferences, and counseling, including prelitigation, Orange Book listings of patents covering FDA-approved drugs, and infringement, enforceability, and validity analysis in the chemical/ pharmaceutical fields. He has been involved as lead counsel in numerous patent interferences, reissues, and reexaminations. Irving has co-authored a multitude of articles and treatises on various patent law topics, including for ABA's Landslide® magazine, "Top 5 Dangers for the AIA Unwary" (April/May 2013). Having taught patents extensively as a hobby for over 30 years at law schools, ABA, AIPLA, IPO, and state IP bar groups, Irving holds a J.D. (1977) from Duke and a B.A., Chemistry, magna cum laude from Utah (1974).



Jin-Long Chen, Ph.D.
Founder & Chief Scientific Officer
NGM Biopharmaceuticals, Inc.

Building an "Old School" Biotech Company to Discover Novel Biological Medicines

NGM Biopharmaceuticals was founded in 2008 in an attempt to build a company dedicated to the discovery and development of novel and transformational medicines. During the last seven years, NGM has assembled a unique research and discovery program that has enabled the identification and validation of novel pathways for metabolic regulation. By leveraging a biology-driven research approach, NGM is in the process of generating a pipeline of new drug candidates as treatments for a variety of serious diseases, including diabetes, obesity and cancer. This singular vision of an organization committed to novel drug discovery has attracted significant funding from the private sector, as well as the interest of leading pharmaceutical companies and the establishment of multiple research collaborations.

As NGM's founder, Dr. Chen will discuss his views on entrepreneurship and its importance in drug discovery, his approaches for building a biopharmaceutical company from scratch, and the company's progress towards realizing the aspiration to discover important new medicines for the treatment of grievous illnesses.

About the speaker

Jin-Long Chen, Ph.D. is the Founder and current Chief Scientific Officer at NGM Biopharmaceuticals, Inc., a privately held company focused on the use of emerging human biology to discover and validate novel drug targets and factors. Founded in 2008, NGM implemented an integrated approach to elucidate the roles of previously unidentified regulators in the systemic control of metabolism towards the development of transformational medicines for the treatment of metabolic and cardiovascular diseases.

Dr. Chen has over 20 years of experience in the biopharmaceutical industry, beginning his professional career at Tularik, where he was instrumental in establishing and directing Tularik's drug discovery efforts in metabolic disease, including diabetes and obesity. In addition, Dr. Chen pioneered powerful platform approaches to discover novel drug targets by identifying and characterizing orphan receptors and their ligands. This research not only opened up opportunities to study new aspects of biology and physiology across multiple disease areas, but also led to important contributions to the development pipeline, including T-131 (now INT-131). During his tenure at Tularik, he held a series of positions with increasing scope and responsibility, culminating with his appointment as Vice President, Biology. Following the acquisition of Tularik by Amgen in 2004, Dr. Chen initially assumed responsibility for guiding Biology research, and all aspects of target discovery, across the therapeutic areas at Amgen South San Francisco, including metabolic disorders, oncology, inflammation / immunology and neurosciences. Subsequently, he was appointed to the role of Vice President, Research at Amgen Inc., with responsibility for leading the company's global research efforts in support of new drug discovery for the treatment of human diseases of metabolism, bone, mineral balance and muscle. His pioneering work on a broad array of targets at both Amgen and Tularik, not only opened up opportunities to study new aspects of biology and physiology across multiple disease areas, but also led to contributions of multiple drug candidates to the development pipelines of these organizations, including Repatha™ (evolocumab), a novel investigational anti-PCSK9 antibody that lowers low-density lipoprotein cholesterol (LDL-C)-lowering.

Dr. Chen received a B.S. in Nutrition and Food Science from Fu-Jen Catholic University, and a M.S. in biochemistry from National Taiwan University. He completed his graduate training at the University of California, Berkeley in 1994, receiving a Ph.D. for his research on the mechanisms of transcription carried out in the laboratory of Robert Tjian.

Aaron Sato, Ph.D.
Vice President of Research & Development
Sutro Biopharma

Sutro Biopharma: A Bay Area Biotech Veteran that Reinvented Itself

Sutro Biopharma was founded over 10 years ago and in that time, has reinvented itself many times to suit the needs of the industry. In this presentation, I will review how we changed our business strategy from a pure "Make" technology to one that empowers "Discovery and Make", which has allowed us to land several transformational deals.

About the speaker

Aaron Sato is Vice President of Research at Sutro Biopharma, where his team uses a proprietary bacterial cell-free expression system to discover and produce high value protein therapeutics, such as ADCs, bispecifics, and naked antibodies. Prior to joining Sutro, Aaron was Sr. Director of Antibody Engineering at OncoMed Pharmaceuticals, where his team discovered several antibodies for its clinical pipeline. Before this, he was Sr. Director of Lead Discovery at Dyax Corp., where he oversaw multiple external collaborations with major pharma & biotech companies. He received a doctorate in chemistry from MIT and a bachelor's degree in chemistry from the University of Puget Sound. In his free time, Aaron is an avid runner and skier and loves to take advantage of everything Northern California has to offer. Today, Aaron is going to tell us about how Sutro can express antibodies and fragments thereof in a cell free system, reformat them into a whole host of different bispecific frameworks, and produce homogenous site-specific antibody drug conjugates with single or dual warheads.

Stephen Thau, J.D.
Partner
Morrison & Foerster LLP

Status Update for Deals and Financings in Biotechnology

The biotechnology sector is in the midst of one of its most active periods for high-profile mega-deals. What's happening below the surface is more complicated. Mr. Thau will review recent deal trends in biotechnology-pharma partnerships, venture capital financing and M&A.

About the speaker

Stephen Thau is a corporate partner whose practice focuses on the representation of life science, medical device, health IT, software, clean tech and other technology companies in transactional matters, including public and private financings, licensing, collaborations and strategic alliances, and mergers and acquisitions. He also represents venture capital and investment banking firms in public and private financing transactions. He has represented companies and investors in over 100 venture capital and debt financing transactions, numerous public offerings, and dozens of public and private M&A transactions and strategic collaboration agreements.

Mr. Thau is a member of the Board of BayBio, Northern California's leading life science association. He is a frequent speaker on venture capital financings and served on the faculty at the 2005 and 2007 Emerging Entrepreneurs workshops at Stanford University. Mr. Thau is recommended as a leading lawyer by PLC Which lawyer? 2011, Best Lawyers in America 2013, Chambers USA 2014, and Legal 500 US 2013. He was named to the Daily Journal's inaugural list of 25 leading biotech lawyers in California, in 2011 and was recognized as a "Life Sciences Star" by LMG Life Sciences in 2014.

Mr. Thau re-joined Morrison & Foerster in 2008 after having practiced corporate law for ten years at Venture Law Group and Heller Ehrman LLP. Mr. Thau began his legal practice as a patent and securities litigator at Morrison & Foerster and served as a law clerk to the Hon. Vaughn R. Walker in the United States District Court in the Northern District of California. He graduated Order of the Coif from Stanford Law School, where he was managing editor of the Stanford Law Review, and graduated magna cum laude from Harvard College in Biology.

Ming Zhao, Ph.D.
Program Director, SBIR Development Center
National Cancer Institute

NCI SBIR & STTR: Advancing the Commercialization of New Cancer Innovation

The Federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at National Cancer Institute (NCI) are a critical source of non-dilutive financing for early stage companies in cancer areas, providing over $120M in fiscal year 2015 to develop next generation technologies. These funding programs help fill the gap in the availability of early stage funding created when investors and strategic partners moved towards clinical-stage investments. SBIR funds serve as a key bridge between initial angel funding and more significant angel capital, venture capital, or strategic partnerships. NCI SBIR & STTR is currently funding over 400 projects in the areas of health IT, diagnostics, imaging, devices, therapeutics and tools for basic research. In this presentation, Dr. Ming Zhao, a program director at the NCI SBIR Development Center, will talk about funding opportunities for early-stage ventures from the NCI. The presentation will provide an overview of SBIR/STTR eligibility requirements, NIH SBIR/STTR process and new cancer-focused grant funding opportunities from NCI, new NCI SBIR/STTR initiatives and practical strategies on how to successfully submit competitive research proposals.

About the speaker

Ming Zhao, Ph.D., is a Program Director in the SBIR Development Center at the National Cancer Institute (NCI). In this role, Dr. Zhao develops and manages SBIR/STTR programs and contracts focused on cancer therapeutics, molecular diagnostics and medical imaging. Prior to his appointment at SBIR, Dr. Zhao was a Program Director in the Center to Reduce Cancer Health Disparities (CRCHD) at the NCI. During his tenure at CRCHD, he managed various NCI/NIH programs such as Community Networks Program Centers (CNPC, a program with a total of $117M & 23 Centers) and Geographical Management of Cancer Health Disparities Program (GMaP) as well as R01/R21 grants. Before Dr. Zhao joined NCI, he worked as a senior scientist at the GE Global Research Center and as a scientist at Pfizer. Dr. Zhao received his B.S./M.S. degrees from Shandong University, China, and his Ph.D. in molecular biology and biochemistry from the Department of Biological Sciences, Wayne State University. He carried out postdoctoral research at both the University of Michigan Medical School and Wayne State University.

Darren Ji, Ph.D., M.B.A.
Global Head & Vice President
Asia and Emerging Markets Partnering, F. Hoffmann-La Roche

Maximizing the Capital Efficiency for Drug R&D through Creative Partnerships

A key element to ensure a successful drug development is to have continuous fund to cover the costly research and development activities. In the recent years various creative models have evolved to allow risk-award sharing among biotech companies, major drug houses and VC communities. In this talk Dr. Ji will share some of the industry frameworks that allow win-win drug development efforts. The talk is aimed to inspire further creative thinking around how to best maximize the use of capitals to efficiently advance cutting-edge sciences to the bedside.

About the speaker

Dr. Darren Ji is currently Vice President and Global Head, Asia and Emerging Markets Partnering, Roche. Darren was previously President and CEO of NPBiosciences, a biotech company based in Singapore. Prior to that Darren founded and served as CEO of PharmaLegacy Laboratories, which is a Shanghai-based Contract Research Organization specializing in preclinical pharmacology services. Darren spent 11 years at the Procter & Gamble Company with progressive responsibilities in drug research and development, and lastly as director of bioscience business development in East Asia. Darren previously served as a Board Director, and Shanghai regional leader of the BayHelix Group, a global organization of Chinese business leaders in life sciences. Darren obtained his medical degree from China Medical University, China; a Ph.D. from the University of Sheffield, UK; and an M.B.A. from University of Chicago, USA.

Jimmy Z. Zhang, Ph.D., M.B.A.
Vice President, Transactions
J&J Innovation, Asia Pacific

New Ways to Source and Fund Innovations

The presentation will discuss challenges and opportunities in Asia Pacific that are unique under current economic environment. I will also discuss J&J's new approach to innovation, funding strategies, portfolio management and transactions.

About the speaker

Dr. Jimmy Zhang is Vice President, Transactions, Johnson & Johnson Innovation, based in Shanghai. He's responsible for transactional and partnership management activities and strategy in Asia Pacific region in pharmaceuticals, medical devices & diagnostics and consumer products, and also responsible for fund relationship and partnership in the region.

Before joining J&J, Jimmy was the Managing Director, MSD Early Investments – Greater China at Merck & Co. He's responsible for Merck's venture capital investments, licensing, acquisitions, external research collaboration, and alliance/partnership management in Greater China. Jimmy was a Senior Vice President at Synergenics, LLC, a professional service and venture firm founded and led by Dr. Bill Rutter, one of the founding fathers and pioneers of the biotech industry. Synergenics invests and manages early-stage companies in drug discovery, vaccine, diagnostics, and healthcare IT. Jimmy was responsible for the business development and operations of Synergenics and some of its portfolio companies, and their businesses in China. Jimmy was previously a consultant at McKinsey & Company, a registered patent agent in the Palo Alto office of Morrison & Foerster, and a project manager at Chiron Corporation (now part of Novartis).

Jimmy received his B.S. in biochemistry from Nanjing University, and Ph.D. in biomedical sciences from the University of Texas Southwestern Medical Center at Dallas, where he worked closely with three Nobel Laureates. While studying his MBA in MIT Sloan School of Management, Jimmy was elected as the treasurer of MIT Graduate Student Council. He was also a finalist of the 12th Annual MIT $50K Entrepreneurship Competition.

Jimmy published in Cell, Nature, Neuron, and JBC, and holds multiple patents. Jimmy is a founding member and the immediate previous Chairman, Board of Directors of BayHelix Group, a prestigious non-profit organization of Chinese life sciences business leaders. Jimmy is also the Strategic Advisor to both ChinaSF and China Committee of Bay Area Council, and a guest/adjunct professor at Tongji University, Shanghai. Jimmy is a frequently invited speaker and panelist at bio-pharma conferences and hi-tech meetings on business development and doing business between US and China. He is often quoted in both US and Chinese news media.

Chengbin Wu, Ph.D.
Chief Scientific Officer & President of Research & Development
Shanghai CP Guojian Pharmaceutical Co., Ltd.

Developing Therapeutic Antibodies in China: Biosimilars and Beyond

The success of CP GuoJian, a China-based antibody development company, has demonstrated the fast growth of biologics R&D in China over the past 10 years. China has its unique strength in discovery and clinical research, and the bioprocess and manufacturing industry has matured rapidly. Although the earlier antibody development focused mostly on biosimilars, many companies are moving towards developing second generation and novel biologics products. This talk will provide an overview of biologics R&D in China, and address innovative biologics development capabilities and pipeline strategies at CP Guojian.

About the speaker

Dr. Chengbin Wu is the Chief Scientific Officer and President of R&D at Shanghai CP Guojian Pharmaceutical Co., a leading China-based biopharmaceutical company focusing on developing therapeutic antibodies to treat various diseases. Previously he was the Senior VP Biologics at ChemPartner, where he built a world-class antibody R&D platform. Before that he was a Volwiler Associate Fellow at Abbott laboratories where he led several biologics programs into the clinic. Dr. Wu has extensive experience in engineering and therapeutic development of monoclonal antibodies. He is the primary inventor of the DVD-Ig technology, a novel bi-specific antibody-based technology platform for developing next generation protein therapeutics. Dr. Wu received his Ph.D. degree from the University of Georgia, USA, and postdoctoral training at Beth Israel Deaconess Medical Center, Harvard Medical School.

Dechao (Michael) Yu, Ph.D.
President & Chief Executive Officer
Innovent Biologics, Inc.

Innovative Biologics in China: Challenges and Opportunities

There is little innovation in biopharmaceutical industry in China and limited success in translational research as more than 96% of China's biotherapeutics sales comes from biosimilars which has enjoyed a 30%+ CAGR over the past five years. Conbercept, a bispecific antibody that specifically blocks both VEGF and placental growth factor (PlGF), represents the successful development of the very first innovative antibody product in China, which is protected by global intellectual property. This product was approved by China FDA in 2013 for marketing for age-related macular degeneration in China while is currently in phase II/III trials for oncology. As an inventor and the leading developer of Conbercept, I would like to share with audience the lesson that I have learned during the development of this product particularly the experience about how to do effective translational research in China. Our recent partnership with Eli Lilly represents the historic deal struck between a domestic biotech company and a global pharmaceutical company.

Key points:

- Opportunity and challenges of biopharmaceutical industry in China
- Successful development of China's first novel antibody for the treatment of ocular disease and cancers: what we have learned
- Out-licensing and co-developing of a novel monoclonal antibody to Eli Lilly represent the historic milestone in China for innovative biologics

About the speaker

Michael Yu, Ph.D., has been the Chairman, President and Chief Executive Officer of Innovent Biologics (www.innoventbio.com), a leading biologics company in China, since its inception in 2011. Innovent has raised over $280 million from equity, the largest private financing in the biopharmaceutical industry in China and entered a strategic partnership with Eli Lilly, a historic deal struck between a domestic biotech company and a global pharmaceutical company. Prior to the position, Dr. Yu was a co-founder, President and CEO of Chengdu Kanghong Biotech (Kanghong Biotech) since its inception in 2006 until 2011. During his tenure at Kanghong Biotech Dr. Yu built the company to be one of the most promising biopharmaceutical companies in China by rapidly conducting clinical development of four novel antibody products with a first BLA approved for an innovative monoclonal antibody in China, Conbercept. Dr. Yu served as founding President and CEO of Kanghong Sagent Pharmaceuticals (KSP) from 2006 to 2009, a joint venture who has manufactured and currently marketed 5 injectable drugs in the US. Prior to founding Kanghong Biotech and KSP, Dr. Yu was Vice President of Research and Development at Applied Genetics (USA) and Calyon (USA). The latter was acquired by Cell Genesys (USA) in 2001 where he worked for three years following the acquisition.

Dr. Yu is the inventor of the world's first oncolytic virus product, Oncorine (an oncology product) and an anti-angiogenic agent Conbercept (a drug for ocular diseases and oncology), which has made him the only Chinese who invented and developed two Class I innovative drugs in China.

Weidong Jiang, Ph.D.
Chief Scientific Officer & Vice President
Henlius Biopharmaceuticals, Inc.

Antibody Therapeutics in China: a Challenging Pathway

Henlius Biopharmaceuticals Inc. focuses on development and commercialization of mAb-based therapeutics using state-of-the-art technologies. Founded in California in 2009, Henlius became a leading antibody biosimilar company in China in recent years, with 5 biosimilar antibodies filed IND and one in clinical trial in China. I will share with you how we reached to this stage from start, and how we are going to move forward with more innovative antibody projects in our pipelines. A couple of detailed case studies from our biosimilar programs and a biobetter antibody will be presented to display challenges in the pathway towards clinical studies. As a biosimilar pioneer, we obtained the first biosimilar antibody IND approval by Chinese CDE even before the biosimilar guidelines are discussed and published. We are currently advancing our first innovative antibody program in preclinical studies, and planning for IND filing in multiple countries by the end of this year.

About the speaker

Dr. Weidong Jiang is a cofounder of Henlius Biopharmaceuticals, Inc. in U.S. He is also Senior Vice President and Chief Scientific Officer of Shanghai Henlius Biotech Co., Ltd., a joint venture formed by Henlius and Fosun Pharma in 2009 to develop antibody therapeutics. Dr. Jiang has more than 20 years of working experience in many biotech companies, including Catalyst Biosciences Inc., Vasgene Therapeutics Inc., Applied Molecular Evolution Inc. (subsidiary of Eli Lilly), and Chemgenics (acquired by Millennium). He has expertise in the field of drug screening and development, particularly in research and development of antibody therapeutics and other protein biologics. He holds a Ph.D. degree from Giessen University in Germany, a Master degree from Shanghai Institute of Cell Biology, Chinese academy of Sciences, and a Bachelor degree from Zhejiang University.

Lan Huang, Ph.D.
Co-Founder & Chief Executive Officer
BeyondSpring Pharmaceuticals, Inc.

New US-China Integration Model for Innovative Drug Development for the Global Market

BeyondSpring, Dr. Huang's fourth entrepreneur venture, was formed to tackle the highly unsustainable cost problem with innovative drug discovery. BeyondSpring integrates global clinical resources – especially clinical resources from China – to bring a paradigm shift to the R&D model so that innovative drugs can be developed in a more time-efficient and cost-efficient manner. BeyondSpring's first case study is its lead asset, a phase III-ready immune-oncology agent Plinabulin. Plinabulin has composition and use patents granted in 35 countries in the world. For the pivotal global trial in second line NSCLC, after consultation with US FDA, BeyondSpring will enroll 75% of patients in China and the remainder in the US and other western countries, which is the key to save time and cost for Plinabulin development. China's vast clinical resources, tremendous oncology market and government support give BeyondSpring much opportunities. For additional indication development of Plinabulin, US actually offers great opportunities in proof-of-concept clinical studies. However, to execute this efficient model, there are many challenges to overcome, which will be detailed in the talk.

About the speaker

Dr. Huang has been a serial entrepreneur in the biotechnology industry in China and the United States for the past decade. She has successfully co-founded and sold a number of healthcare companies. She was the recipient of "Thousand Talent Innovator Award" in China in 2009. Her current venture BeyondSpring Pharmaceuticals, Inc. employs scalable US-China integration model to develop innovative therapies at low cost, fast speed for global value. Its lead asset Plinabulin, a targeted NSCLC drug, will initiate global phase III trial in NSCLC in Q2 2015. BeyondSpring's investors include HBM Partners, Roche Ventures, Forward Ventures, and Shenzhen Sangel Venture.

Dr. Huang is the inventor of a number of biotech products for cancer and dermatology indications. She co-founded Wuxi MTLH Biotechnology Co. Ltd., whose self-designed cancer peptide drug was partnered with Shanghai Pharmaceutical Group in 2010. She co-founded Paramax International, a Clinical CRO company in China, which was sold to a global CRO RPS, then to Warburg Pincus in 2011. In addition, Dr. Huang worked with Forward Ventures, where she led partnering initiatives between Forward's portfolio companies and Chinese pharmaceutical companies. Dr. Huang was trained at Memorial Sloan-Kettering Cancer Center and received her Ph.D. in Chemistry from UC Berkeley, where she won graduating Ph.D. woman award. Her translational research in cancer involving Ras and P53 were published in Science and Nature. Dr. Huang received her B.A., Magna Cum Laude and Phi Beta Kappa, from Lawrence University, where she served as a Trustee. She was additionally educated at Fudan University in Shanghai, China.

2015 CABS

K. Fong Award in Life Sciences

CABS is pleased to announce the winner of the 3rd CABS K. Fong Award in Life Sciences, Dr. Irving L. Weissman.

We offer this award to recognize Professor Weissman's significant contributions to life sciences, in particular, the groundbreaking discovery of hematopoietic stem cells and stem cells of the human central nervous system, and his contributions to understanding pathways of stem cell-to-cancer cell transitions. His pioneering scientific discoveries continue to translate science into better medicine for the patients.

About the CABS K. Fong Award in Life Sciences

About Dr. Kenneth Fong

Dr. Kenneth Fong is currently the founder and chairman of Kenson Ventures, LLC, a company that specializes in crafting development strategy for early-stage biotech companies. Under his leadership, companies that were acquired or went public between 2007 and 2012 are: SA Biosciences (to Qiagen), DHI (to Quidel), Fermenta (to ThermoFisher), Panomics (to Affymetrix), Epitomics (to Abcam), Bioform (IPO) and Optimer (IPO). Prior to establishing Kenson, Ken founded and served as CEO of Clontech Laboratories (1984-1999), which was acquired by Becton Dickinson in 1999. Clontech, a leader in the molecular/cell biology market, was also the largest of its kind founded by an Asian American (400 people, including 65 Ph.D. scientists).

Ken has held a number of leadership positions over the years. He served as the president of the Society of Chinese Bioscientists in North America (ca 2,000 members, 2007-09) and President of the Bay Area AAMA (1987). He was also a member of the Board of Trustees of California State University (2006-2013), the Advisory Board of the College of Science and Engineering at San Francisco State, Board of Associates at the Whitehead Biomedical Institute at MIT and a member of the Committee of 100 (US). Ken has many other philanthropic interests. He was one of the lead supporters for the San Jose Tech Museum, the Chinese Historical Society in San Francisco, the Bioengineering Auditorium at UC San Diego and the Indiana University graduate Seminar Programs. He has provided a number of scholarships to San Francisco State University, Peking University and the CSU students (Kenneth Fong–Hearst endowed Scholarships). In 2006, he was also involved in establishing the Fong Optometry and Medical Library at UC Berkeley and more recently an endowed professorship to Stanford University.

Established in 2013, the CABS K. Fong Award in Life Sciences is presented annually to recognize those individuals who make significant contributions in the life sciences and biopharmaceutical industry including outstanding scientific findings, recognized efforts in promoting life science education and initiatives in improving the life science community, and those who bring therapeutic breakthroughs to the market and improve healthcare and quality of life.

Candidates must be nominated by an active member of CABS. Selection criteria are based on a candidate's accomplishments in life sciences and contribution to the life science community, including the following:

- Proven achievements in therapeutic breakthroughs (including discovery, process or clinical development), diagnostics or the research reagent/equipment markets
- Significant contribution to the promotion of academic and industrial R&D in biomedical sciences and applications
- Recognized contribution to promoting the global life science community, including CABS, and promoting international collaboration in life sciences

Winners are selected by the CABS Award Selection Committee. The winners will each receive an honorarium and a Plaque of Merit.

CABS Activities

2014 – 2015

Science & Technology Programs

2013-2014 Co-Chairs: Jiangwen Majeti, Ph.D., M.B.A. and Connie Sun, Ph.D.

2014-2015 Co-Chairs: Jianlong Lou, Ph.D. and Jessica Sun, Ph.D.

The CABS Science Technology Committee fosters scientific exchanges in the life science industry. Each year, the committee organizes a series of seminars to discuss the current trends and cutting edge technologies in life sciences, often focusing on a specific approach or technology throughout the year. Members of CABS not only benefit through the seminars but also have the opportunity to interact directly with the speakers who are usually veterans, well-known scholars, or entrepreneurs. In addition, the seminar series also provide members the opportunity to connect with other professionals with diverse areas of specialization, which could lead to unexpected insights. Detailed information for these and other events can be viewed at the CABS homepage (www.cabsweb.org).

Upcoming Events

Drug Delivery/Conjugation: July, 2015
Peripheral Monitoring: September, 2015
Bench, Bedside and Biomarker- Translational Research: October, 2015
Immuno-oncology: November, 2015

Past Events

Advances in Immuno-oncology, An Evolving Approach to Cancer Therapies

September 12, 2014

South San Francisco, CA

The discovery and development of cancer immunotherapy has become an innovative, exciting, and rapidly evolving field as a result of the emerging clinical data indicating that cancer immunotherapy can be efficacious against broad types of tumors beyond melanoma with manageable safety profiles. This workshop invited experts to review the current status and strategy, discuss the available technology, and disclose the new advances in the field of immuno-oncology.

EVENT SPEAKERS

Gary C. Starling, Associate Vice President, Biologics Discovery Operations, Merck Research Laboratories

Patricia Culp, Ph.D., Associate director of Oncology Biologics, AbbVie Biotherapeutics, Inc.

Bryan Irving, Ph.D., Senior Director of Cancer Immunology, CytomX Therapeutics

Shiming Ye, Principal Scientist, Discovery, Oncology Biologics, AbbVie Biotherapeutics, Inc.

Juan C. Jaen, Ph.D., President, Head of R&D, Flexus Biosciences, Inc.

Sanjay Khare, Ph.D., President and CEO, ImmunGene

Advancing Therapeutic Programs through Innovation - Case Studies on Small Molecule Drug Discovery and Development

November 14, 2014

South San Francisco, CA

This workshop was a first in a long while to revisit the topic of small molecule drug discovery and development. Three case studies were presented by their respective project leaders, which explored novel approaches in target selection and medicinal chemistry. They recounted the challenges and successes of their work and shed light on the impact of innovation in advancing these therapeutic programs successfully from discovery to clinical development.

EVENT SPEAKERS

Lianhong Xu, Senior Director, Gilead Sciences

Zhihong Li, Principal Scientist, Amgen

Hang-Jie Zhou, Director of Chemistry, Cleave Biosciences

*Molecular Diagnostics: Technology Development, Applications, and Entrepreneurial Opportunities**

April 18, 2015

Mountain View, CA

Molecular diagnostics is a technique used to analyze biological markers in the genome and proteome. The technique is used to diagnose and monitor disease, detect risk, and decide which therapies work best for individual patients, in other words, personalized and precision medicine. In this workshop, experts in the field discussed the latest technology of molecular diagnostics and their applications, and the future of molecular diagnostics.

The panel discussion benefitted entrepreneurs who are seeking funding in deep sequencing science.

** Co-organized with the Business & Career Development Committee*

EVENT SPEAKERS

Ron Davis (Keynote Speaker), Professor of Biochemistry and Genetics at Stanford University, Director of Genome Technology Center at Stanford University

Dongliang Ge, Director of Bioinformatics at Gilead

Tao Huang, Venture Partner of Cenova Ventures

Yongming Andrew Sun, Senior Staff Bioinformatics Scientist at Ion Torrent

Lisheng Wang, Co-founder of Propel(X)

Wei Zhou, President and CEO of Centrillion Biosciences

CABS Activities
2014 – 2015

Business & Career Development

2013-2014 Co-Chairs: Xiaoli Qin, Ph.D. and Jessica Sang, Ph.D.
2014-2015 Co-Chairs: Cheni Kwok, Ph.D., CLP & Sean Xiang Wu, Ph.D.

Our mission:

• To serve the business and career development needs of our members and the San Francisco Bay Area life sciences community

• To provide our members with interactive, informative platforms and networks to launch, to transition, or to advance their careers in the life sciences industry

• To enable our sponsors to effectively recruit talent, management team, and innovative projects

Upcoming Events

Chindia : Cross Border Life Sciences Entrepreneurship and Transactions. Event co-hosted by the Chinese Bioscience Association (CBA) and EPPIC; supported by CABS BCD and BayHelix
Entrepreneur Club (E-Club) will continue provide a network among existing and future entrepreneurs through workshops and casual lunch meetings.
BCD will organize workshops on interdisciplinary collaboration, such as wearable devices, to foster the collaboration between biosciences and technology fields.

Past Events

Job Search and Interview Workshop

May 28, 2014, Palo Alto, CA

The job search can be a long and stressful process, and a job interview is one of the most drawn-out and intimidating ways of making a first impression. The way an applicant behaves in

the first interview can be highly important in getting the job. However, it is also an opportunity to get on an employer's good side, which can give the applicant a distinct edge over even those with better credentials. In this special event, experienced recruiters and industry elites shared their valuable advice and experience to help attendees succeed in their job search and interview and start their career in biopharmaceutical industry.

EVENT SPEAKERS

Dr. Melisa S. Medrano, Staffing Consultant
Gilead Sciences, Inc.

Ms. Katherine Yagel, Director of Professional Services
Lee Hecht Harrison (LHH)

Mr. Howard Simon, J.D., Chief Operating Officer & General Counsel, DNA2.0

Dr. Leping Li, Vice President of Chemistry
Presidio Pharmaceuticals

Mr. Don Lim, Sr. Recruiter,
Yahoo and previously at Onyx

What Chinese American Professionals Should Know About Trade Secrets and Export Control Cases: Lessons from Civil Lawsuits and Criminal Prosecutions

May 29, 2014, Menlo Park, CA

When a trade secrets case in the U.S. involves a foreign country, more than 60% of the time that foreign country is China. Among the significant criminal trade secrets cases prosecuted by the U.S. Department of Justice (DOJ), more than 80% involve Chinese defendant(s). Among the significant criminal export control cases prosecuted by DOJ, more than one-third is against Chinese defendant(s). Moreover, on average, Chinese defendant(s) get longer sentences. Eli Lilly, Pittsburgh Corning Corp., Motorola, Toray Industries, and DuPont Co. are just several companies whose Chinese employees faced high-profile trade secrets or export control criminal prosecution, some of which took place in the Bay Area. There are many lessons we can learn from those cases that can prevent us from inadvertently making mistakes that may violate trade secrets law and export control regulations.

EVENT SPEAKERS

Zheng Liu, Chief Counsel, Orrick, Herrington & Sutcliffe

Warrington Parker, Partner, Orrick, Herrington & Sutcliffe

Eugene Illovsky, Partner, Morrison Foerster

CABS Workshop: Careers Beyond R&D in Biotech, Part 1

August 23, 2014, Foster City, CA

This year, we organized a 2-part workshop series on "Careers Beyond R&D in Biotech". The workshops provided junior professionals an overall view of the industry and facilitated their long-term career development. A panel discussion on individual department/function in a typical biotech or pharma organization was also held.

PANELISTS

Charlene Liao, Ph.D., Project Team Leader
Portfolio Management & Operations at Genentech

Tony (Dongxiao) Zhang, Ph.D., Co-founder, President and CEO of BlueJay Mobile-Health, Inc.

Shelly Xiong, Ph.D., RAC, Director of Regulatory Affairs at InterMune, Inc.

Ying Gong, Ph.D., Medical Affairs at Genentech

Jennifer Wang, Ph.D., Senior Scientist in Investigational Medicinal Product Quality at Genentech

Toby Freedman, Ph.D., Author and Founder/President of Synapsis Search

CABS Workshop: Careers Beyond R&D in Biotech, Part 2

November 1, 2014, Foster City, CA

This workshop was the second of a 2-part workshop series on "Careers Beyond R&D in Biotech". The workshop and panel continued the discussion on individual department/function in a typical biotech or pharma organization. Panelists gave brief introductions on how each function fits into the organization and what the career path is to get on to it.

PANELISTS

Zhengning Lin, Ph.D., Vice President, Statistics, Statistical Programming, and Data Management at InterMune

Marcus Littman, M.B.A., Director, Medical Surveillance & Coding - Risk Management, Drug Safety & Public Health at Gilead Sciences, Inc.

Irene Xie, M.S., Sr. Manager of Clinical Supply Management at Gilead Sciences, Inc.

Gary Yeung, M.B.A., Head of gRED project management, Genentech/Roche

Haoran Zhao, Ph.D., Senior Project Manager at Genentech

Youling Zou, M.S., M.B.A., Program Manager at Baidu US

2015 Career Advisory Network (CAN) Program Kickoff

March 22, 2015, Foster City, CA

Due to popular demand, BCD launched the CAN program for the 5th consecutive year. CAN is a personalized career advisory platform designed to provide one-on-one interaction between a designated mentor and mentee. Since the inauguration of CAN in 2010, the program has been very successful and we have a growing number of CAN participants. This year, we have a total of 37 mentors from a broad range of functional areas in life sciences committed to serve our program. The CAN kickoff meeting held on 22 March 2015 was a great success with over 70 mentors and prospective mentees participating in this event. Details on the CAN schedule for this year are posted on the CABS website (www.cabsweb.org).

CAN Program Statistics	2010	2011	2012	2013	2014
# Mentors	23	26	28	26	32
# Mentees	32	58	59	62	62
Satisfaction	77%	81%	91%	83%	80%
Continue CAN?	100%	100%	100%	100%	100%

Co-Hosted First Association of Stanford Chinese Students and Scholars (ACSSS) Career Fair

March 21, 2015, Palo Alto, CA

Over 200 participants and 20 companies attended this very successful event. Our program included a panel discussion regarding transitioning to industry from academia. This was followed by a career fair with hiring companies from Applied Materials, Baidu, ThermoFisher Scientific, Wuxi Apptec, Clindata Insight, Labii, ProMab, LakePharma, Sutro Biopharma, 中粮COFC, Medjaden, 北京协同创新研究院 and Linear Dreams.

Legal Workshop: Case Studies - How to Protect and Avoid Legal Problems on Intellectual Property and Trade Secret in Business Partnerships, Tech Transfers, and Cross-Border Deals

April 14, 2015, Menlo Park, CA

When a trade secrets case in the U.S. involves a foreign country, more than 60% of the time that foreign country is China. Among the significant criminal trade secrets cases prosecuted by the U.S. Department of Justice (DOJ), more than 80% involve Chinese defendant(s). Among the significant criminal export control cases prosecuted by DOJ, more than one-third is against Chinese defendant(s). Moreover, on average, Chinese defendant(s) get longer sentences. Eli Lilly, Pittsburgh Corning Corp., Motorola, Toray Industries, and DuPont Co. are just several companies whose Chinese employees faced high-profile trade secrets or export control criminal prosecution, some of which took place in the Bay Area. There are many lessons we can learn from those cases that can prevent us from inadvertently making mistakes that may violate trade secrets law and export control regulations.

This important legal workshop introduced the law on trade secrets and discussed IP & trade secrets issues in business partnerships, tech transfers, international travel and cross-border deals.

EVENT SPEAKERS

Zheng Liu, Of Counsel, Orrick, Herrington & Sutcliffe

Tom Nolan, Trial lawyer, NAB Law LLC

Heather Newberry, Government Agent, FBI-San Francisco Division

Nikolas Shenkin, Government Agent, FBI-San Francisco Division

Aaron Wong, Government Agent, FBI-San Francisco Division

CABS Activities
2014 – 2015



International Collaboration

2013-2014 Co-Chairs: Cheni Kwok, Ph.D., CLP and Zhenhai Shen, Ph.D., M.B.A.

2014-2015 Co-Chairs: Yan Wang, Ph.D. and Zhenhai Shen, Ph.D., M.B.A.

The CABS International Collaboration Committee (ICC) strives to promote international collaborations with various life sciences organizations and serves as a bridge that connects our members to life sciences communities in the Pacific Rim countries. This year we arranged our annual CABS entrepreneur delegation trip to China and hosted multiple Bay Area events for life sciences organizations from the Pacific Rim countries to facilitate networking and partnership opportunities with CABS members.

Planned Events

We will host a reunion of the 2014 fall delegation and a forum with CABS members in the Bay Area to share the highlights of the visit to China as well as the perception of the latest trends for life sciences in China.

We will communicate with biotech and biopharmaceutical companies in China to get to know their need in life sciences and introduce the appropriate projects of CABS members to promote collaboration. This will be beneficial for the possible 2015 delegation trip to China.

In order to get to know how to start and run a biotech company from scratch, we will organize the trips for CABS members to visit some biotech companies in the bay area and in California.

We will continue to invite the people who are working and/or have set up a company in China to give talks about their experience.

We will coordinate with the Business & Career Development Committee to have a seminar and/or lunch meeting on topics such as career development, entrepreneurship, collaboration between China and US, etc.

Past Events

2014 CABS Delegation to Cities and Science Parks in China

October 29 to November 10, 2014

The co-chair of 2013-2014 ICC Dr. Cheni Kwok, in collaboration with our executive committee, organized a delegation of life sciences entrepreneurs to attend two international conferences and to visit science parks and life sciences companies in Taizhou, Nanjing, Zibo, Hangzhou, and Shanghai. The key objectives of this delegation were:

- To promote international life sciences collaborations between US and China
- T o enable our entrepreneurial members to evaluate opportunities to establish or to expand their operations in China
- To gain insight from successful Chinese-based life sciences companies
- To establish new CABS strategic collaborations with science parks and local governments in China
- To raise awareness of CABS as a major Chinese-American life sciences professional organization
- To provide a platform to share the latest trends of research and development in US with Chinese life sciences companies/organizations and to facilitate the recruitment of US life sciences talents, entrepreneurs and professionals to China

Highlights of the Delegation:

- International Entrepreneurship Conference at Taizhou (2014年中国医药城（泰州）高层次人才创新创业洽谈会)
  - Poster presentation by each invited CABS delegation
  - The CABS delegation visited several companies established by entrepreneurs from San Francisco Bay Area and San Diego at China Medical City (CMC) in Taizhou
- Nanjing Jiangning High-Tech Industrial Park (南京江宁高新园)
- Zibo High Tech Industrial Development Zone (淄博国家高新技术产业开发区)
  - CABS visited our latest strategic partner at Shandong Zibo. Our delegation attended several meetings with government officials and local biopharmaceutical leaders to discuss latest trends of our industry, to showcase our delegates' projects and to plan for joint events in 2015
- International Talent Conference at Hangzhou (2014浙江•杭州国际人才交流与项目合作大会)
  - Dr. Jackson Gong's project was selected by the conference organizing committee as one of the outstanding overseas projects. Dr. Kwok provided an

Hangzhou Talent Conference

oral presentation introducing CABS and Dr. Gong's project at the outstanding overseas project presentation event (海外社团优秀创新创业项目发布)

- Visit to Shanghai Medicilon and Luoxin Biological Technology in Shanghai

Hosted a Visit by the CEO of Qilu Pharmaceutical

May 31, 2014

The CABS president, president-elect and EC co-chairs met Qilu Pharmaceutical's Mrs. Li Yan (CEO) and Yaning Wang, M.D., M.S. (SVP) to explore potential opportunities to collaborate. Qilu Pharmaceutical is one of the leading pharmaceutical companies in China. It focuses on developing, manufacturing and marketing of generic drugs and active pharmaceutical ingredients in the therapeutic areas of Oncology, Cerebrovascular & Cardiovascular, Infections, Psychological and Neurological System, Respiratory System, Ophthalmological Diseases.

CABS and Alliance Event - Meeting with Delegates from Nanjing Jiangning

August 15, 2014, San Francisco, CA

NanJing Jiangning High-tech Industrial Park delegation visited the Bay Area in mid-August and hosted a reception event in the evening of August 15th. The reception provided a setting for the Bay Area talent in the biopharma and medical technologies industries and the delegation from Jiangning to meet and exchange ideas. Entrepreneurs had the opportunity to learn about the business environment in Jiangning, presented business plans, and collected feedback for further Nanjing 321 Proposal application.

Met the Delegation from Zibo-Hanhai Science Park in Silicon Valley

September 5, 2014, Silicon Valley, CA

IC members met with the delegation to discuss how to collaborate with Zibo-Hanhai Science Park to promote scientific program and organize scientific seminars.

Hosted a Visit by Senior Executives from Shangdong Luoxin Pharmaceutical

September 18, 2014

CABS EC members met the senior executives to introduce CABS and to explore potential ways to work with Luoxin. Luoxin Biotechnology is the newly founded R&D center of Shandong Luoxin Pharmaceuticals in Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai. Shandong Luoxin Pharmaceuticals was founded in 1995. The headquarters is in Linyi, Shandong. To build a strong pipeline of products to support future growth, Luoxin decided to establish a R&D center in Shanghai.

Co-Organized a Talent Recruiting Event with Kelun Pharmaceutical

September 27, 2014, Foster City, CA

CABS helped Kelun Pharmaceutical to organize a recruiting event in Foster City. Kelun's Chief Scientific Officer presented Kelun and the key positions that they were recruiting to more than 40 CABS members. They also held further one-on-one discussions for those who wanted to discuss opportunities in more detail. This is the Kelun's first visit to CABS, and they became a sponsor and would seek continued collaboration with CABS.

Panel Discussion on the Work and Entrepreneur Experience in China

February 28, 2015, Burlingame, CA

At this panel discussion, the panelists shared their working experience in China and compared it with that in the US. In addition, they provided insight in terms of how to balance family life and work. This benefited the audience who are considering going back to China to work or start a business so they understood what to expect, what to be aware of, and how to be more effective.

Dr. Yan Wang hosted the discussion with three panelists. They are Dr. Minxue Zhang, Professor, Director of Nucleic Acid Testing Research Center, Suzhou Institute of Biomedical Engineering and Technology (SIBET), Chinese Academy of Sciences (CAS) and Founder of GWP Biotechnology Ltd. Inc.; Dr. Shawn Qian, Co-Founder, President & CEO at NeuPharma; and Dr. Sean Hu, Founder and Senior Vice President of Dophen Biomed. Highlights of the discussions included current opportunities and challenges in China; the exploration of opportunities for collaboration in China; and how to balance work in China and family life in the Bay Area.

PANELISTS

Minxue Zheng, Ph.D., President and CEO, GWP Biotechnology

Shawn Qian, Ph.D., Co-Founder, President & CEO at NeuPharma

Sean Hu, Ph.D., Founder and Senior Vice President of Dophen Biomed

CABS Activities
2014 – 2015

Social Life

2013-2014 Co-Chairs: Jessica Sun, Ph.D. and Xiaoyu Xu, Ph.D

2014-2015 Co-Chairs: Bo Lian, Ph.D. and Jian Zhang, Ph.D.

The Social Life Committee (SLC) is dedicated to serving our members with high quality indoor and outdoor activities. Within the CABS community, SLC intends to provide a bridge for connection and interaction, enrich and improve quality of life by organizing fun and memorable experiences, and sharing knowhow and experience.

SLC actively organizes interesting talks, social events, and fun activities; promotes networking between CABS members; attract new members; and collaborates with other societies to enrich the community.

The key objectives of CABS Social Life Committee are:

- *To serve the social connection and life skill needs of our CABS members through fun and educational activities*
- *Provide networking and social interaction opportunities for the CABS family*
- *Bring opportunities for friendship and caring while inspiring through sharing experiences*
- *Promote healthy and positive lifestyle for our CABS life science community*

Planned Events

CABS Summer BBQ 2015, August 8, Foster City Boothbay Park
Group hiking and outdoor recreational activities
Team sports
Financial management and Tax related talk or seminar
Talk on teenager and family mental health

Past Events

Annual Summer BBQ Networking Picnic

August 17, 2014 , Foster City, CA

Over 200 CABS members, families and friends attended this well-organized party. In addition to the delicious food, people also enjoyed mingling with friends, playing sports and enjoying lots of other activities. We thank the participants for the support; we congratulate those on winning the lucky draws; we once again thank our volunteers for the tremendous help. And we also look forward to more and more people participating in our future events and activities!

2015 CABS Chinese New Year Party

February 14, 2015, Foster City, CA

The old year leaves amidst the falling snow 瑞雪纷飞辞旧岁
The new spring comes with the shining glow 旭日东升迎新春.

Happy Chinese New Year!!! CABS kicked off the Year of the Sheep/Goat/Ram with exciting CABS traditional New Year Festivities during our annual Chinese New Year Party!

Activities included, singing and dancing, Beijing opera, live musical entertainment, spring festival couplets and conundrum, and much more!

There were games for children and lucky draws for everybody! And the top lucky raffle winner went home with a new Apple iPad!!! People reconnected with old friends and made new ones and had fun celebrating Chinese New Year 2015 together!

Education Seminar - How to Prepare Your Kids for College Application

March 29, 2015, Redwood City, CA

Many parents have concerns and need help with the college application process for their children. Nankai University alumnus and senior education adviser Dr. Amy Meng shared her knowledge about how to help students create a successful college application to schools such as Yale, Columbia, Cornell, etc. In the seminar, she shared with parents the three key essentials for college applications and how to arrange summer activities for students of different ages.

** Co-hosted with the International Collaboration Committee*

Membership

2013-2014 Co-Chairs: Ruben Luo, Ph.D. and Yang Tian, Ph.D.
2014-2015 Co-Chairs: Liping Meng, Ph.D. and Yang Tian, Ph.D.

Past Events

CABS & ACE Panel Discussion -- Entrepreneurship in Biotechnology - Opportunities and Challenges

September 8, 2014, Berkeley, CA

CABS and the Association of Chinese Entrepreneurs (ACE) at Berkeley co-hosted a 2nd CABS on-campus event: Panel discussion on Entrepreneurship in Biotechnology, Opportunities and Challenges. The panel featured Dr. Guo-liang Yu, Executive chairman at Crown Biosciences, Dr. Ying-Fei Wei, CEO at Elixirin, Dr. Shawn Lee, Founder and President, CPC Scientific, and Dr. Tao Huang, Legal and IP counsel at Cenova Ventures. Each panelist has more than 20 years of bio entrepreneurship, experience and mentoring.

PANELISTS

Guo-Liang Yu, Ph.D., Executive Chairman at Crown Biosciences

Ying-Fei Wei, Ph.D., CEO, Elixirin

Shawn Lee, Ph.D., Founder and CEO, CPC Scientific

Tao Huang, Ph.D., J.D., Legal and IP Counsel, Cenova Ventures

临沂应用科学城位于山东省临沂市北城新区科研用地的核心区，建于2013年4月，占地150亩，总建筑面积16万平方米，共有联合成长大厦、科技企业加速器、学术交流中心、专家公寓 4 个功能区。

临沂应用科学城作为高层次人才聚集地和创新创业综合服务平台，将打造成为集高端人才创业园、支柱产业和骨干企业联合研发中心、科研院所、科技企业加速器、大学科技园、产学研合作创新示范基地和国际科技合作基地等功能为一体的科技绿色智慧园区。

临沂应用科学城示范效应日益显现，以生物医药、先进装备、新材料等产业为重点，目前已建设实验动物与药物安全性评价中心、新药筛选中心，吸引中德创新中心、中国中医科学院、国际科技合作基地、朗玛峰创投公司等38家机构、企业入驻。

未来3-5年内，通过与周边大学、总部基地、医院等机构深度融合，将全面满足高层次人才工作、生活、休闲、交流等方面的需求，为海内外人才到临沂创新创业提供优质环境。

科技支撑发展　人才引领未来

临沂市位于中国山东省东南部，人口1090万，面积1.72万平方公里，是山东省人口最多、面积最大的市。近年来，临沂市大力实施“科教兴市”、“人才强市”战略，先后建成了国家级高新技术产业开发区、国家级经济技术开发区，建设临沂应用科学城等科技创新平台550多家，与20多个国家和地区的110多家高等院校、科研院所开展了科技合作与交流。

支持政策

1、50-500万元科研经费或创业启动资金资助。
2、不少于100平方米的工作场所、200平方米的创业孵化场所，免收3年租金。
3、最高50万元购房补贴，或连续5年每年5万元租房补贴。
4、新入选国家“千人计划”专家、山东省“泰山学者”海外特聘专家等，一次性奖励100万元。
5、随迁配偶安置、子女入学、医疗保障等方面开设绿色通道。

Conference Notes

CABS
Chinese American Biopharmaceutical Society
北美华人生物医药协会

ABOUT CABS

The Chinese American Biopharmaceutical Society (CABS) is a purely volunteer-run, non-profit, non-political organization.

CABS is hosting the BioPacific Conference 2015, aka the 17th annual conference of the society, with the goal of bringing scientists, executives, intellect property protection professionals, venture capitalists and other biopharmaceutical professionals from the San Francisco Bay Area and around the world to enjoy a day of excitement and stimulation, share successful stories in medical science field and health promotion via collaboration and partnership, discuss the latest advances in the biotechnology/pharmaceutical industry, and the daily increasing opportunities in Asia/Pacific countries.

CABS is unique in that it enjoys an excellent reputation in China and also has a strong relationship with a number of science parks, life sciences institutions and companies in China. In recent years, CABS has played an increasingly important role in bridging the biopharmaceutical communities across the Pacific Ocean. In particular, the BioPacific Conference serves as an important venue for peer-to-peer networking to exchange information, explore collaboration, and recruit talent.

Take advantage of CABS membership rates and additional member benefits for $30/year by visiting www.cabsweb.org/CABSweb/fregister.jsp

For more info and to register, please visit:

www.cabsweb.org
www.biopacificconference.org